| 361 | 2 | 114 |
| 下载次数 | 被引频次 | 阅读次数 |
人腺病毒（Human adenovirus,HAdV）是一种无包膜的二十面体对称型线性双链DNA病毒，属于腺病毒科、哺乳动物腺病毒属。HAdV常感染6个月至5岁的儿童，可引起肺炎、急性胃肠炎等疾病，腺病毒肺炎是造成婴幼儿肺炎致残和死亡的重要原因之一。目前临床上缺乏理想的特异性药物，而中和抗体能够与病毒结合从而特异性抑制病毒感染，在HAdV的治疗中展示出良好的应用前景。本文综述了近10年HAdV中和抗体的研究进展，总结了HAdV中和抗体的靶向位点、抗原表位以及中和活性，为进一步研发HAdV中和抗体药物提供参考。
Abstract：Human adenovirus(HAdV), which belongs to adenoviridae family and mammalian adenoviruses genus, is a non-enveloped icosahedral symmetrical virus with linear-double-stranded DNA. Children from 6 months to 5-year-old are susceptible to be infected with HAdV, presenting pneumonia, acute gastroenteritis or other diseases. HAdV infection in infants with pneumonia is one of the important causes of disability and mortality. What's worse, there is no ideal drug specific to HAdV infection in clinic practice at present. However, HAdV infection can be specifically inhibited by the combination of neutralizing antibodies(NAs) and corresponding antigens, showing a broad prospect of NAs in the treatment of HAdV. In this paper, the studies on NAs of HAdV in recent 10 years were collected, and the target sites, epitopes as well as the neutralizing activity of NA of HAdV mentioned in these studies were summarized, which provide references for further research and development of HAdV neutralizing antibody drugs.
[1]王艳，谭丙绣，侯喆，等.人腺病毒流行病学研究进展[J].国际病毒学杂志，2023,30(3):255-258.DOI:10.3760/cma.j.issn.1673-4092.2023.03.017
[2]段亚丽，朱云，徐保平，等.儿童社区获得性肺炎中人腺病毒感染的多中心研究[J].中华儿科杂志，2019,57(1):27-32.DOI:10.3760/cma.j.issn.0578-1310.2019.01.008
[3]国家卫生健康委员会，国家中医药管理局.儿童腺病毒肺炎诊疗规范（2019年版）[J].传染病信息，2019,32(4):293-298.DOI:10.3969/j.issn.1007-8134.2019.04.002.
[4]Kim D,Lee E,Eom J,et al.Prevalence and burden of human adenovirus-associated acute respiratory illness in the republic of Korea military,2013 to 2022[J].JKorean Med Sci,2024,39(4):e38.DOI:10.3346/jkms.2024.39.e38.
[5]Koren MA,Arnold JC,Fairchok MP,et al.Typespecific clinical characteristics of adenovirus-associated influenza-like illness at five US military medical centers,2009-2014[J].Influenza Other Respir Viruses,2016,10(5):414-420.DOI:10.1111/irv.12392.
[6]Barraza EM,Ludwig SL,Gaydos JC,et al.Reemergence of adenovirus type 4 acute respiratory disease in military trainees:report of an outbreak during a lapse in vaccination[J].J Infect Dis,1999,179(6):1531-1533.DOI:10.1086/314772.
[7]胡广义，张文增，吴殚.2019-2021年北京市顺义区腺病毒引起的学校流感样病例暴发疫情流行特征分析[J].中国病毒病杂志，2021,11(6):472-475.DOI:10.16505/j.2095-0136.2021.0061.
[8]Kujawski SA,Lu X,Schneider E,et al.Outbreaks of adenovirus-associated respiratory illness on 5 college campuses in the United States,2018-2019[J].Clin Infect Dis,2021,72(11):1992-1999.DOI:10.1093/cid/ciaa465.
[9]Georgi F,Andriasyan V,Witte R,et al.The FDA-approved drug nelfinavir inhibits lytic cell-free but not cell-associated nonlytic transmission of human adenovirus[J].Antimicrob Agents Chemother,2020,64(9):e01002-20.DOI:10.1128/aac.01002-20.
[10]Naesens L,Lenaerts L,Andrei G,et al.Antiadenovirus activities of several classes of nucleoside and nucleotide analogues[J].Antimicrob Agents Chemother,2005,49(3):1010-1016.DOI:10.1128/aac.49.3.1010-1016.2005.
[11]Wold WS,Toth K.New drug on the horizon for treating adenovirus[J].Expert Opin Pharmacother,2015,16 (14):2095-2099.DOI:10.1517/14656566.2015.1083975.
[12]Hiwarkar P,Amrolia P,Sivaprakasam P,et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant[J].Blood,2017,129(14):2033-2037.DOI:10.1182/blood-2016-11-749721.
[13]Matthes-Martin S,Feuchtinger T,Shaw PJ,et al.European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation:summary of ECIL-4(2011)[J].Transpl Infect Dis,2012,14(6):555-563.DOI:10.1111/tid.12022.
[14]Danziger-Isakov L,Steinbach WJ,Paulsen G,et al.Amulticenter consortium to define the epidemiology and outcomes of pediatric solid organ transplant recipients with inpatient respiratory virus infection[J].J Pediatric Infect Dis Soc,2019,8(3):197-204.DOI:10.1093/jpids/piy024.
[15]Heemskerk B,Lankester AC,van Vreeswijk T,et al.Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients[J].JInfect Dis,2005,191(4):520-530.DOI:10.1086/427513.
[16]Londeree J,Winterberg PD,Garro R,et al.Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients:a case series[J].Pediatr Transplant,2020,24(7):e13769.DOI:10.1111/petr.13769.
[17]Shrestha LB,Tedla N,Bull RA.Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants[J].Front Immunol,2021,12:752003.DOI:10.3389/fimmu.2021.752003.
[18]Gao X,Fan L,Zheng B,et al.Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain[J].Hum Vaccin Immunother,2022,18 (5):2055373.DOI:10.1080/21645515.2022.2055373.
[19]Vanshylla K,Fan C,Wunsch M,et al.Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers[J].Cell Host Microbe,2022,30 (1):69-82.e10.DOI:10.1016/j.chom.2021.12.010.
[20]Haynes BF,Wiehe K,Borrow P,et al.Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies[J].Nat Rev Immunol,2023,23(3):142-158.DOI:10.1038/s41577-022-00753-w.
[21]黄国虹，许文波.腺病毒新型别的研究进展[J].病毒学报，2013,29(3):342-348.DOI:10.13242/j.cnki.bingduxuebao.002397.
[22]张哲，曲章义，王迎晨，等.新型别人腺病毒的研究进展[J].国际病毒学杂志，2019,26(4):282-285.DOI:10.3760/cma.j.issn.1673-4092.2019.04.018.
[23]杨传宇，赵林清.人腺病毒流行病学研究进展[J].病毒学报，2021,37(3):732-739.DOI:10.13242/j.cnki.bingduxuebao.003974.
[24]Simons-Linares CR,Imam Z,Chahal P.Viralattributed acute pancreatitis:a systematic review[J].Dig Dis Sci,2021,66(7):2162-2172.DOI:10.1007/s10620-020-06531-9.
[25]Garcia-Garcia ML,Calvo Rey C,Del Rosal Rabes T.Pediatric asthma and viral infection[J].Arch Bronconeumol,2016,52(5):269-273.DOI:10.1016/j.arbres.2015.11.008.
[26]Jagannathan G,Weins A,Daniel E,et al.The pathologic spectrum of adenovirus nephritis in the kidney allograft[J].Kidney Int,2023,103(2):378-390.DOI:10.1016/j.kint.2022.10.025.
[27]Rabaan AA,Bakhrebah MA,Nassar MS,et al.Suspected adenovirus causing an emerging HEPATITISamong children below 10 years:a review[J].Pathogens,2022,11 (7):712.DOI:10.3390/pathogens11070712.
[28]Zhang XF,Tan CB,Yao ZX,et al.Adenovirus infection-associated central nervous system disease in children[J].Pediatr Infect Dis J,2021,40(3):205-208.DOI:10.1097/inf.0000000000003000.
[29]Valdés O,Acosta B,Pi?ón A,et al.First report on fatal myocarditis associated with adenovirus infection in Cuba[J].J Med Virol,2008,80(10):1756-1761.DOI:10.1002/jmv.21274.
[30]Portes SA,Volot?o Ede M,Rocha MS,et al.A nonenteric adenovirus A12 gastroenteritis outbreak in Rio de Janeiro,Brazi[lJ].Mem Inst Oswaldo Cruz,2016,111(6):403-406.DOI:10.1590/0074-02760160030.
[31]G?tting J,Baier C,Panagiota V,et al.High genetic stability of co-circulating human adenovirus type 31lineages over 59 years[J].Virus Evol,2022,8(2):veac067.DOI:10.1093/ve/veac067.
[32]Giladi N,Herman J.Pharyngoconjunctival fever[J].Arch Dis Child,1984,59(12):1182-1183.DOI:10.1136/adc.59.12.1182.
[33]Mao NY,Zhu Z,Zhang Y,et al.Current status of human adenovirus infection in China[J].World JPediatr,2022,18(8):533-537.DOI:10.1007/s12519-022-00568-8.
[34]Yu Z,Zeng Z,Zhang J,et al.Fatal communityacquired pneumonia in children caused by re-emergent human adenovirus 7d associated with higher severity of illness and fatality rate[J].Sci Rep,2016,6:37216.DOI:10.1038/srep37216.
[35]Walsh MP,Seto J,Jones MS,et al.Computational analysis identifies human adenovirus type 55 as a reemergent acute respiratory disease pathogen[J].J Clin Microbiol,2010,48(3):991-993.DOI:10.1128/jcm.01694-09.
[36]Gu J,Su QQ,Zuo TT,et al.Adenovirus diseases:a systematic review and meta-analysis of 228 case reports[J].Infection,2021,49(1):1-13.DOI:10.1007/s15010-020-01484-7.
[37]Shiramizu T,Satoh T,Jinushi K,et al.Renal allograft dysfunction with acute hemorrhagic cystitis caused by adenovirus in a recipient of a transplanted kidney[J].Tokai J Exp Clin Med,1986,11(5):371-375.
[38]Masaki K,Asakura T,Sakurai K,et al.Adenovirus type 5 community-acquired pneumonia in an immunocompetent patien[tJ].BMJ Case Rep,2019,12(4):e228914.DOI:10.1136/bcr-2018-228914.
[39]Murrah KA,Turner RL,Pang B,et al.Replication of type 5 adenovirus promotes middle ear infection by Streptococcus pneumoniae in the chinchilla model of otitis media[J].Pathog Dis,2015,73(2):1-8.DOI:10.1111/2049-632x.12216.
[40]Zheng X,Lu X,Erdman DD,et al.Identification of adenoviruses in specimens from high-risk pediatric stem cell transplant recipients and controls[J].J Clin Microbiol,2008,46(1):317-320.DOI:10.1128/jcm.01585-07.
[41]van Bijsterveld OP,de Jong JC,Muzerie CJ,et al.Pharyngoconjunctival fever caused by adenovirus type 19[J].Ophthalmologica,1978,177(3):134-139.DOI:10.1159/000308757.
[42]Adhikary AK,Banik U.Human adenovirus type 8:the major agent of epidemic keratoconjunctivitis(EKC)[J].J Clin Virol,2014,61(4):477-486.DOI:10.1016/j.jcv.2014.10.015.
[43]Jhanji V,Chan TC,Li EY,et al.Adenoviral keratoconjunctivitis[J].Surv Ophthalmol,2015,60(5):435-443.DOI:10.1016/j.survophthal.2015.04.001.
[44]Kajon AE,Lamson DM,Bair CR,et al.Adenovirus type 4 respiratory infections among civilian adults,northeastern United States,2011-20151[J].Emerg Infect Dis,2018,24(2):201-209.DOI:10.3201/eid2402.171407.
[45]Ariga T,Shimada Y,Ohgami K,et al.New genome type of adenovirus serotype 4 caused nosocomial infections associated with epidemic conjunctivitis in Japan[J].J Clin Microbiol,2004,42(8):3644-3648.DOI:10 .1128/jcm.42.8.3644-3648.2004.
[46]Lee B,Damon CF,Platts-Mills JA.Pediatric acute gastroenteritis associated with adenovirus 40/41 in lowincome and middle-income countries[J].Curr Opin Infect Dis,2020,33(5):398-403.DOI:10.1097/qco.0000000000000663.
[47]Jones MS II,Harrach B,Ganac RD,et al.New adenovirus species found in a patient presenting with gastroenteritis[J].J Virol,2007,81(11):5978-5984.DOI:10.1128/jvi.02650-06.
[48]Shiratsuchi T,Rai U,Kaneko I,et al.A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII[J].Vaccine,2017,35(50):6990-7000.DOI:10.1016/j.vaccine.2017.10.066.
[49]Martín-González N,Hernando-Pérez M,Condezo GN,et al.Adenovirus major core protein condenses DNA in clusters and bundles,modulating genome release and capsid internal pressure[J].Nucleic Acids Res,2019,47(17):9231-9242.DOI:10.1093/nar/gkz687.
[50]Lutz P,Puvion-Dutilleul F,Lutz Y,et al.Nucleoplasmic and nucleolar distribution of the adenovirus IVa2 gene product[J].J Virol,1996,70(6):3449-3460.DOI:10.1128/jvi.70.6.3449-3460.1996.
[51]Hoeben RC,Uil TG.Adenovirus DNA replication[J].Cold Spring Harb Perspect Biol,2013,5(3):a013003.DOI:10.1101/cshperspect.a013003.
[52]Mangel WF,San Martín C.Structure,function and dynamics in adenovirus maturation[J].Viruses,2014,6(11):4536-4570.DOI:10.3390/v6114536.
[53]Reddy VS,Barry MA.Structural organization and protein-protein interactions in human adenovirus capsid[J].Subcell Biochem,2021,96:503-518.DOI:10.1007/978-3-030-58971-4_16.
[54]Nemerow GR,Pache L,Reddy V,et al.Insights into adenovirus host cell interactions from structural studies[J].Virology,2009,384(2):380-388.DOI:10.1016/j.virol.2008.10.016.
[55]Nelson AL,Dhimolea E,Reichert JM.Development trends for human monoclonal antibody therapeutics[J].Nat Rev Drug Discov,2010,9:767-774.DOI:10.1038/nrd3229.
[56]Hong B,Wen Y,Ying T.Recent progress on neutralizing antibodies against hepatitis B virus and its implications[J].Infect Disord Drug Targets,2019,19(3):213-223.DOI:10.2174/1871526518666180628122400.
[57]Gaudinski MR,Coates EE,Novik L,et al.Safety,tolerability,pharmacokinetics,and immunogenicity of the therapeutic monoclonal antibody MAb114 targeting Ebola virus glycoprotein(VRC 608):an open-label phase 1 study[J].Lancet,2019,393(10174):889-898.DOI:10.1016/S0140-6736(19)30036-4.
[58]Liu MC,Xu Q,Li TT,et al.Prevalence of human infection with respiratory adenovirus in China:a systematic review and meta-analysis[J].PLoS Negl Trop Dis,2023,17(2):e0011151.DOI:10.1371/journal.pntd.0011151.
[59]Varghese R,Mikyas Y,Stewart PL,et al.Postentry neutralization of adenovirus type 5 by an antihexon antibody[J].J Virol,2004,78(22):12320-12332.DOI:10.1128/jvi.78.22.12320-12332.2004.
[60]Tian X,Li C,Xue C,et al.Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3[J].Virus Res,2013,177(2):189-193.DOI:10.1016/j.virusres.2013.08.013.
[61]Liu M,Tian X,Li X,et al.Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7(HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector[J].PLoSOne,2014,9(7):e103058.DOI:10.1371/journal.pone.0103058.
[62]Tian X,Qiu H,Zhou Z,et al.Identification of a critical and conformational neutralizing epitope in human adenovirus type 4 hexon[J].J Virol,2018,92(2):e01643-17.DOI:10.1128/jvi.01643-17.
[63]Wang R,Lu J,Zhou Q,et al.A murine monoclonal antibody with potent neutralization ability against human adenovirus 7[J].Front Cell Infect Microbiol,2019,9:417.DOI:10.3389/fcimb.2019.00417.
[64]Lu J,Wang R,Huang Y,et al.A novel human monoclonal antibody potently neutralizes human adenovirus serotype 7 by primarily targeting the adenovirus hexon protein[J].Virology,2020,543:20-26.DOI:10.1016/j.virol.2019.12.005.
[65]Chen L,Lu J,Wang R,et al.Humanization and characterization of a murine monoclonal neutralizing antibody against human adenovirus 7[J].Virology,2023,583:36-44.DOI:10.1016/j.virol.2023.04.008.
[66]Liu X,Li Z,Li X,et al.Neutralizing monoclonal antibodies protect against human adenovirus type 55infection in transgenic mice and tree shrews[J].Emerg Microbes Infect,2024,13(1):2307513.DOI:10.1080/22221751.2024.2307513.
[67]Tian X,Fan Y,Liu Z,et al.Broadly neutralizing monoclonal antibodies against human adenovirus types55,14p,7,and 11 generated with recombinant type 11fiber knob[J].Emerg Microbes Infect,2018,7(1):206.DOI:10.1038/s41426-018-0197-8.
[68]Chen L,Lu J,Yue J,et al.A humanized anti-human adenovirus 55 monoclonal antibody with good neutralization ability[J].Front Immunol,2023,14:1132822.DOI:10.3389/fimmu.2023.1132822.
[69]Hong SS,Habib NA,Franqueville L,et al.Identification of adenovirus(ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors[J].J Virol,2003,77(19):10366-10375.DOI:10.1128/jvi.77.19.10366-10375.2003.
[70]Toogood CI,Hay RT.DNA sequence of the adenovirus type 41 hexon gene and predicted structure of the protein[J].J Gen Virol,1988,69 (Pt 9):2291-2301.DOI:10.1099/0022-1317-69-9-2291.
[71]Qiu H,Li X,Tian X,et al.Serotype-specific neutralizing antibody epitopes of human adenovirus type3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions[J].J Virol,2012,86(15):7964-7975.DOI:10.1128/jvi.07076-11.
[72]Feng Y,Sun X,Ye X,et al.Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity[J].Virology,2018,518:272-283.DOI:10.1016/j.virol.2018.03.002.
[73]Su X,Tian X,Jiang Z,et al.Human adenovirus serotype 3 vector packaged by a rare serotype 14 hexon[J].PLoS One,2016,11(6):e0156984.DOI:10.1371/journal.pone.0156984.
[74]Liu T,Zhou Z,Tian X,et al.A recombinant trivalent vaccine candidate against human adenovirus types 3,7,and 55[J].Vaccine,2018,36(16):2199-2206.DOI:10.1016/j.vaccine.2018.02.050.
[75]Gallardo J,Pérez-Illana M,Martín-González N,et al.Adenovirus structure:what is new?[J].Int J Mol Sci,2021,22(10):5240.DOI:10.3390/ijms22105240.
[76]Liu T,Fan Y,Li X,et al.Identification of adenovirus neutralizing antigens using capsid chimeric viruses[J].Virus Res,2018,256:100-106.DOI:10.1016/j.virusres.2018.08.007.
[77]Tian X,Su X,Li H,et al.Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon[J].Virus Res,2011,160(1-2):214-220.DOI:10.1016/j.virusres.2011.06.017.
[78]Yu B,Dong J,Wang C,et al.Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species:potential application for adenovirus seroepidemiology[J].J Gen Virol,2014,95(pt 7):1564-1573.DOI:10.1099/vir.0.064832-0.
[79]Hu K,Fu M,Guan X,et al.Penton base induces better protective immune responses than fiber and hexon as a subunit vaccine candidate against adenoviruses[J].Vaccine,2018,36(29):4287-4297.DOI:10.1016/j.vaccine.2018.05.118.
[80]Cao Y,Wang J,Jian F,et al.Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies[J].Nature,2022,602(7898):657-663.DOI: 10.1038/s41586-021-04385-3.
[81]Grunst MW,Qin Z,Dodero-Rojas E,et al.Structure and inhibition of SARS-CoV-2 spike refolding in membranes[J].Science,2024,385(6710):757-765.DOI:10.1126/science.adn5658.
[82]Li C,Zhan W,Yang Z,et al.Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific singledomain antibody[J].Cell,2022,185(8):1389-1401.e18.DOI:10.1016/j.cell.2022.03.009.
[83]Sun X,Liu C,Lu X,et al.Unique binding pattern for a lineage of human antibodies with broad reactivity against influenza A virus[J].Nat Commun,2022,13(1):2378.DOI:10.1038/s41467-022-29950-w.
[84]Wang C,Li W,Drabek D,et al.A human monoclonal antibody blocking SARS-CoV-2 infection[J].Nat Commun,2020,11(1):2251.DOI:10.1038/s41467-020-16256-y.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004639
中图分类号:R392
引用信息:
[1]颜可昕,王佳楠,杨乐涵,等.人腺病毒中和抗体研究进展[J].病毒学报,2025,41(05):1581-1593.DOI:10.13242/j.cnki.bingduxuebao.004639.
基金信息:
上海交通大学医学院大学生创新性训练计划(项目号：1723Y025)，题目：人B族腺病毒广谱中和抗体的筛选~~
2024-07-24
2024
2024-08-31
2024-11-25
2024
1
2024-12-25
2024-12-25
2024-12-25